Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination With Various Anticancer Therapies in Patients With Advanced Solid Tumors
Conditions
Interventions
SLC-3010
Gemcitabine
Locations
9
United States
Selecxine Investigator site
Sarasota, Florida, United States
Selecxine Investigator site
Detroit, Michigan, United States
Selecxine Investigator site
Oklahoma City, Oklahoma, United States
Selecxine Investigator site
Waratah, New South Wales, Australia
Selecxine Investigator site
Brentwood, Perth, Australia
Selecxine Investigator site
Seoul, Jongno-gu, South Korea
Start Date
December 21, 2022
Primary Completion Date
February 1, 2026
Completion Date
January 1, 2028
Last Updated
September 21, 2023
NCT06898450
NCT05720117
NCT05719558
NCT05098132
NCT07477743
NCT06598800
Lead Sponsor
Selecxine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions